A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Abstract Background The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might improve response. Vismodegib is an HPI approved f...

Full description

Bibliographic Details
Main Authors: Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Hematology & Oncology
Subjects:
Vismodegib
Ruxolitinib
Myelofibrosis
Hedgehog pathway inhibitor
Hematopoiesis
Hematologic malignances
Online Access:http://link.springer.com/article/10.1186/s13045-018-0661-x

Internet

http://link.springer.com/article/10.1186/s13045-018-0661-x

Similar Items